Mabwell Announces the NMPA Approval of Novel B7-H3 ADC (7MW3711) for IND
SHANGHAI, July 22, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its clinical trial application of 7MW3711 for advanced malignant solid tumor was approved by the National...
Mabwell Announces the NMPA Approval of Novel Trop-2 ADC (9MW2921) for IND
SHANGHAI, July 19, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its clinical trial application of 9MW2921 for advanced solid tumor was approved by the National Medical...